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clinical case report
Aggressive prolactinoma in a child 
related to germline mutation in 
the ARYL hydrocarbon receptor 
interacting protein (AIP) gene
Prolactinoma agressivo na infância relacionado à mutação 
no gene da proteína ARYL hidrocarbono (AIP)
Luciana Ansaneli Naves1, Marie-Lise Jaffrain-Rea2,  
Sergio Alberto Cunha Vêncio3, Clausmir Zaneti Jacomini4, 
Luiz Augusto Casulari1, Adrian F. Daly5, Albert Beckers5
SUMMARY
The objective of this study was to describe a familial screening for AIP mutations in the context of 
aggressive prolactinoma in childhood. A 12-year-old boy, presented headaches and bilateral he-
mianopsia. He had adequate height and weight for his age (50th percentile), Tanner stage G1 P1. His 
bone age was 10 years. Prolactin was 10.560 ng/mL (3-25), FSH and LH were undetectable, IGF-1, 
TSH, Free T4, ACTH, and cortisol were within normal ranges. MRI showed a pituitary macroadeno-
ma, 5.3 X 4.0 X 3.5 cm with compression of the optic chiasm, bilateral cavernous sinus invasion, 
encasement of carotids, and extension to clivus. Surgical debulking was performed. Resistance to 
cabergoline was characterized and he was submitted to two surgeries and radiotherapy. Immuno-
histochemical evaluation included prolactin, ACTH, GH, FSH, LH,AIP, c-erb B2, Ki-67, and p53. Geno-
mic DNA was isolated from the index case and 48 relatives, PCR and sequencing were performed. 
A germline A195V mutation in AIP was identified in the index case and in five asymptomatic 
relatives. Germline mutations in the AIP gene may be involved in the predisposition to pituitary 
adenoma formation, as cause or co-factor in pathogenesis of aggressive tumors in young pa-
tients. Arq Bras Endocrinol Metab. 2010;54(8):761-7
SUMÁRIO
O objetivo deste estudo foi descrever o rastreamento familiar para mutações AIP em paciente 
portador de prolactinoma agressivo e resistente na infância. Um menino de 12 anos foi avalia-
do com queixa de cefaleia e hemianopsia bitemporal. Apresentava peso e altura adequados 
para a idade (percentil 50), estádio puberal Tanner G1 P1 e idade óssea de 10 anos. Prolacti-
na 10.560 ng/mL (3-25), FSH e LH indetectáveis, IGF-1, TSH, T4 livre, ACTH, e cortisol normais. 
A ressonância magnética de sela evidenciou macroadenoma hipofisário, 53 X 40 X 35 mm com 
compressão de quiasma ótico, invasão de seios cavernosos, envolvimento de carótidas internas 
e extensão para o clivus. Foi realizada descompressão cirúrgica por via transesfenoidal e carac-
terizada resistência a doses máximas de cabergolina, sendo o paciente operado por mais duas 
vezes e submetido à radioterapia. Realizou-se imuno-histoquímica para prolactina, ACTH, GH, 
FSH, LH, AIP, c-erb B2, Ki-67 e p53. O DNA genômico foi extraído do caso índice e de 48 familia-
res, e PCR e sequenciamento. Uma mutação A195V na AIP foi detectada no paciente e em cinco 
parentes assintomáticos. As mutações no gene da AIP podem estar envolvidas na predisposição 
à formação de adenomas, como causa ou cofator na patogênese de tumores agressivos em 
jovens. Arq Bras Endocrinol Metab. 2010;54(8):761-7 
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Clinical and molecular aspects of macroprolactinoma in a child with AIP mutation
INTRODUCTION
Clinically relevant pituitary adenomas have a preva-lence of 1 case per 1064-1289 of the population 
and prolactinomas are the most common comprising 
57%-66% of the total (1,2). As with all pituitary adeno-
mas, prolactinomas are unfrequent in childhood, only 
about 3.5%-8.5% of pituitary adenomas are diagnosed 
before the age of 20 years and an indolent course may 
mean that tumors occurring in adolescents are not ac-
tually diagnosed until early adulthood (3,4). 
Clinical presentation in childhood is variable and symp-
toms related to tumor growth are the most prevalent. In 
young children, decrease in growth velocity is a rare symp-
tom, what could contribute to subclinical disease evolu-
tion and the delay in diagnosis. Impairment of gonadal 
axis is the most frequent endocrine disorder in late child-
hood and adolescence, leading to delayed puberty (4-6).
First-line treatment of prolactinomas relies on do-
pamine agonists, such as, cabergoline, and relative or 
complete resistance is very uncommon. Clinical factors 
associated with tumor aggressiveness and resistance to 
dopamine agonists include young age at onset, male 
gender, large tumor size or cavernous sinus invasion at 
diagnosis (7-10). 
Despite many genetic abnormalities being de-
scribed, the molecular pathophysiology of prolacti-
nomas, particularly those with an aggressive clinical 
course, remains largely obscure. Recently, germline 
mutations in the aryl hydrocarbon receptor interacting 
protein (AIP) gene, were reported to be involved in the 
predisposition to pituitary adenoma formation (11,12). 
Patients with AIP mutations have pituitary adeno-
mas at a younger age, which are often large at diagno-
sis, suggesting an aggressive phenotype. These tumors 
usually occur in the familial isolated pituitary adenomas 
(FIPA) setting (13,14) and sporadic pituitary tumors 
firstly appeared to be very rare (15-16). Recently, AIP 
mutations related to sporadic tumors have been increas-
ingly reported in young patients (17,18). In a recently 
published international collaborative study in 96 patients 
with pituitary adenomas and AIP mutations, 10.4% had 
a familial AIP mutation but no known relatives with pi-
tuitary adenomas, and 30.2% were apparently sporadic 
cases. Most are somatotropinomas with characteristics 
that have now been well documented, followed by pro-
lactinomas, and rare non-secreting adenomas (17).
We report here the clinical and pathological features 
of a young patient with a highly aggressive and invasive 
prolactinoma that was resistant to dopamine agonists, 
in whom a germline AIP mutation was identified, and 
extensive familial screening was performed.
SUBJECTS AND METHODS
The study was conducted in accordance with the guide-
lines of the Declaration of Helsinki and genetic analysis 
was approved by the Ethics Committee of the Univer-
sity of Brasilia. The subjects and guardians provided 
written informed consent for the genetic and other in-
vestigations performed.
Histology and immunohistochemistry
The tumor specimen was fixed in 10% formalin and 
paraffin-embedded. Hematoxylin and eosin staining 
was performed in all sections. Immunohistochemical 
evaluation using the Streptavidin-Biotin system (Dako 
Coorporation, polyclonal antibodies) included pro-
lactin (dilution 1:2000), FSH (clone C10-1:50), LH 
(clone C93-1:50), TSH (clone 42-1:50), GH (1:2000), 
ACTH (clone O2A3-1:100), c-erb B2 (oncoprotein C, 
1:400), and monoclonal antibodies (Dako Coorpo-
ration) were used for Ki-67 (Mib-1, 1:100) and p53 
(DO7, 1:50). Mouse monoclonal antibodies directed 
against AIP (clone 35-2) and AHR (clone RPT9, re-
ferred to as “N-mAb”) were performed as previously 
described (18). 
Genetic screening
Genomic DNA was isolated from peripheral blood of the 
participating subjects. Primers used for the analysis of the 
AIP exonic and flanking intronic sequences are as report-
ed by Vierimaa and cols. and the PCR reaction/sequenc-
ing were performed as reported previously (11-13). 
CASE REPORT
A male patient was firstly evaluated at the age of 12 
years, complaining of headaches and visual loss. There 
was no family history of pituitary adenomas or other 
endocrine diseases. Physical examination demonstrated 
adequate height and weight for chronological age (50th 
percentile), Tanner stage G1 P1. Bone age was 10 years. 
Bilateral hemianopsia was confirmed by computed visual 
field. MRI showed a pituitary macroadenoma, 5.3 X 4.0 
X 3.5 cm with compression of the optic chiasm, cystic 
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cavernous sinus invasion with total (left) or near-total 
(right) encasement of internal carotids, and extension to 
pontine cistern and clivus (Figure 1). The first prolac-
tin obtained was 226 ng/mL and after a 1:100 dilu-
tion, the hook effect was confirmed and prolactin was 
10.560 ng/mL (normal range 3-25 ng/mL), FSH and 
LH were undetectable, IGF-1, TSH, Free T4, ACTH, 
and cortisol were within normal ranges for gender and 
age (Table 1). Due to imminent threat to the patient’s 
vision, surgical debulking via transsphenoidal approach 
was performed, and tumor volume reduced to 4.3 X 3.5 
X 2.0 cm (Figure 2). The patient was treated with caber-
goline after surgery, starting at a dose of 2 mg/week for 
two months, 3 mg/week for a further three months and 
then 3.5 mg/week for two years. However, the lowest 
prolactin level achieved was 3.792 ng/mL. Tumor size 
decreased by only a further 20% after two years of medi-
cal treatment (Table 1). The patient was reoperated on 
via the transcranial route, followed by a second trans-
sphenoidal approach one month later, achieving signifi-
cant debulking, but intracavernous remnants persisted. 
Fractionated stereotaxic radiotherapy was performed 
and the linear accelerator-delivered dose of 50.4 Gy (5 × 
1.8 Gy weekly), with a 2-mm safety margin was admin-
istered. After 10 months of radiation follow-up, at pa-
tient’s chronological age of 15 years and 10 months, no 
spontaneous signs of puberty were observed (Tanner G1 
P1), his height was 165.5 cm (Target Height = 171,5 
± 9 cm). Bone age was 11 years of age. A thyrotrophic 
deficiency was detected and levothyroxin 75 mg was pre-
scribed. The prolactin nadir after multiple treatments 
was of 2,198 ng/mL, FSH 1.9 mUI/mL (pre-pubertal 
levels < 6), LH 0.5 mUI/mL (pre-pubertal levels < 5), 
Testosterone 37 ng/dL (30-580). Cabergoline treat-
ment was maintained at a dose of 3.5 grams/week, and 
no growth hormone replacement was prescribed. 
Figure 1. Pre-operatory MRI showed a pituitary macroadenoma, 5.3 X 4.0 
X 3.5 cm with compression of optic chiasm, cystic degeneration of the 
suprasellar portion, and bilateral cavernous sinus invasion with total (left) 
or near-total (right) encasement of internal carotids, and extension to 
pontine cistern and clivus.
Figure 2. Post-operatory MRI showed a pituitary macroadenoma, 4.3 X 3.5 
X 2.0 cm with bilateral cavernous sinus invasion with total (left) or near-
total (right) encasement of internal carotids, and extension to pontine 
cistern and clivus.











12 y 12 y,3 mo 13 y,10 mo 14 y, 5 mo 15 y,10 mo
Prolactin (2-21 ng/mL) Pre-dilution: 226
Post-dilution: 10,560
6,589 3,792 3,130 2,198
FSH(< 6 mUI/mL) 1.8 3.3 2.1 1.3 1.9
LH (< 6 mUI/mL) 0.1 2.2 1.5 0.5 0.5
Testosterone (15-305 ng/dL) 22.5 13.2 84.7 67.3 37
TSH(0,5-5 uIU/mL) 1.05 0.55 0.7 0.3 0.4
FT4 (0.7-1.6 ng/mL) 1.2 1.1 1.0 0.9 1.0
Cortisol (8-25 ng/mL) 14.0 12.9 13.8 10 11.9
ACTH (10-60 pg/mL) 16.8 19.0 14.1 15.1 14.5
IGF-1 (143-693 ng/mL) 142 98.1 112 141 130
Tumor diameter* 5.3 X 4.0 X 3.5
(38.76 cm3)
4.3 X 3.5 X 2.0
(15.72 cm3)
4.0 X 3.0 X 2.0
(12.54 cm3)
3.5 X 3.0 X 1.8
(9.87 cm3)
3.0 X 3.0 X 1.6
(7.54 cm3)
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Figure 4. Semiquantitative immunostaining for (A) AIP (X40) and (B) AHR (X10). The AIP staiting was 10% in adenomatous cells (A) and AHR was negative (B). 
A B
Figure 3. Semiquantitative immunostaining for (a) prolactin (+++/4), (b) KI-67 (++/4), p53-clone DO-7 (+/4) and c-erb B2 (negative). Staining was 
classified according to the guidelines of Brazilian Society of Pathology: +, 10% cells positive; ++, 10%-25% cells positive; +++, 21%-50% cells positive; 






Immunohistochemistry studies have confirmed strong 
(+++) staining of the tumor for prolactin, and nega-
tive staining for FSH, LH, GH, TSH, and ACTH. 
Ki-67 and p53 labeling indexes were 25% and 10% of 
tumor cells, respectively, no membrane immunoreac-
tivity for c-erbB2 was observed (Figure 3). The tumor 
sample was weakly positive for AIP immunostaining 
and negative for AHR immunostaining, respectively 
(Figure 4).
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Genetic analyses and familial screening
In the affected patient a germline A195V mutation 
in the AIP was identified. Thereafter, comprehensive 
genealogical data were collected from the family and 
screening for the mutation was performed in all con-
senting subjects. The genealogical tree for the family 
was constructed using Genopro-Beta® program, and 
comprised 48 individuals in 15 sub-families. Screening 
identified five additional asymptomatic carriers of the 
A195V mutation across three generations; the muta-
tion was traced to the maternal grandmother of the 
index case. In the five asymptomatic A195V mutation 
carriers, clinical, hormonal (basal prolactin, FSH, LH, 
cortisol, ACTH, GH, and IGF-1), and radiological (pi-
tuitary MRI) screening was performed. No pituitary 
adenomas have been diagnosed in these five individuals 
until the present moment. 
Study of the frequency of A195V nucleotide changes 
control individuals in Brazilian population
We studied 177 control subjects in Brasilia, with no 
diagnosis of endocrine diseases. These subjects were 
assessed for the presence of AIP polymorphisms. The 
A-V amino acid substitution at position 195 was not 
observed in control subjects. These results were com-
pared to 298 non-MEN1, non-CNC acromegalic pa-
tients, in order to compose the control group database 
recently published in the context of an international 
collaborative study (17). Neither in non-AIP mutated 
acromegalic patients nor in the control subjects, was 
this A-V substitution observed, therefore the polymor-
phism at this position was excluded.
Study of the frequency of A195V nucleotide changes 
in other species
Genbank was consulted and reported sequences of the 
AIP protein in other species indicate that it belongs 
to a highly conserved region. In a minority of aquatic 
species (Dario Rerio and Xenopus), but not in others 
(Salmo Salar), the V195 residue is lost together with 
significant differences in the whole region, strongly 
suggesting interaction of AIP with different proteins. 
AIP protein length varies between 328 and 356 amino 
acids. Of note, the V195A change was not observed in 
any species (Table 2).
DISCUSSION
Pituitary adenomas in children, although rare, can 
pose particularly difficult clinical problems when they 
are invasive or require multi-modal therapy as they can 
interfere with growth and pubertal development. The 
search for predictors and prognostic factors is an open 
field, despite the large number of molecular abnormali-
ties described to date in the pituitary tumor tissue. The 
current case illustrates many of the existing clinical and 
pathological challenges in the pediatric pituitary tumor 
setting. Our patient maintained the growth velocity 
and adequate height for familial pattern, despite sub-
normal IGF-1 levels, confirming previous reports that 
a clinically evident growth deficit is not a common find-
ing in young patients with prolactinoma (19). Delayed 
puberty related to hyperprolactinemia and gonado-
tropic deficiency after multiple pituitary interventions 
was observed and is in accordance with previous case 
reports. The resistance to treatment with dopamine 
Clinical and molecular aspects of macroprolactinoma in a child with AIP mutation
Table 2. Comparison between AIP protein sequences among species 
Species Genbank AIP Sequence Homology around Valine 195 (human)
Homo sapiens NF_003968 330 aa ..mtdeekakavplihgegnrlyreghvkeaaakyydaiaclknlgmkeqpgs..
Macaca mulata NF_001181242 330 aa ..mtdeekakavplihgegnrlyreghvkeaaakyydaiaclknlgmkeqpgs..
Mus musculus NF_057875 330 aa ..mtdeekakavpvihgegnrlyreggvkeaaakyydaiaclknlgmkeqpgs..
Rattus norvegicus NF_758830 330 aa ..mtdeekakavplihgegnrlyreggvkeaaakyydaiaclknlgmkeqpgs..
Bos taurus NF_898905 330 aa ..mtdeekakavpvihgegnrlyreghvkeaaakyydaiaclknlgmkeqpgs..
Eqqus caballus NF_001075406 356 aa ..mtdaekakavpvihgegnrlyreghvkeaaakyydaiaclknlgmkeqpgs..
Gallus gallus NF_989800 327 aa ..mtdeeklqavplihgegnelyrqgkkvreaatkyydaiaclkn1gmkeqpgs..
Salmo salar NF_001133532 342 aa ..mtddeklevvpqlhvegnalykkgdvkeaaekyhnaiaclknlgmkerpgd.
Dario rerio NF_999877 342 aa ..mtddeklgaipqiheegnalfksgdisgaaekyynaiaclksslqmkerpgd...
Xenopus NF_001096219 328 aa ..mtdgekmeavpvlhgegnglykggktndaaakyyeaiaclkslqmkegpgs..
The human V195 residue in the AIP protein sequence is considered to be one of the 10 amino-acids involved in the binding surface of the TPR region (see NP_003968). Reported sequences of the AIP 
protein in other species indicate that it belongs to a highly conserved region, with polymorphisms being recognized around the V195 residue (indicated in bold red), the V195 residue itself being 
conserved (highlighted in green). In a minority of aquatic species (Dario Rerio and Xenopus), but not in others (Salmo Salar), the V195 residue is lost together with significant differences in the whole 
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agonists, specially cabergoline, may be related to do-
pamine-receptor expression in the adenomatous tissue 
(7-10), although tumor aggressiveness may be related 
to AIP mutations in young patients (12,13).
Mutations on AIP may be involved in cell prolif-
eration in several ways: multiple protein-protein inter-
actions may lead in particular to AHR stabilization in 
the cytoplasm, thereby enhancing its ligand-induced 
nuclear translocation, and modulation of specific phos-
phodiesterases in some pituitary cells (16,20,21). The 
role of endocrine disrupters is a field of interest, and 
a recent Italian study evaluated the incidence of pi-
tuitary tumors in the Seveso population exposed to 
2,3,7,8-tetrachlorodibenzo-para-dioxin following an 
industrial accident in 1976, and no statistically signifi-
cant increase of incident pituitary tumors was shown in 
this area (22).
In an unselected series of sporadic pituitary ad-
enoma patients, mutations in AIP are rarely found, 
(15,16,23). However, as most patients with AIP mu-
tation-related pituitary adenomas present with early 
onset tumors, screening for germline AIP mutations 
should be limited to selected groups of sporadic pa-
tients, particularly young patients with somatotropi-
nomas or macroadenomas (17,24). In our patient, a 
V195A missense mutation was observed in the index 
case. Although no functional studies are available, el-
ements arguing for a pathogenetic mutation include: 
1) the lack of V195A alleles among 298 acromegalic 
patients (17) and 177 Brazilian controls, respectively 
2) Valine is highly conserved at 195 position during the 
evolution, as shown in table 2; 3) its identification as 
one out of the few amino acids involved in the binding 
surface of the TPR region, which mediates most of the 
protein-protein interactions of AIP (25).
The same mutation was also be identified in 5 as-
ymptomatic relatives. This suggests a low penetrance 
of the mutation, as already described in most sporadic 
cases (16,17). Noteworthy, modifier genes have been 
proposed to influence the penetrance of AIP muta-
tions in familial and also in sporadic settings (23). In 
this patient we studied some proliferative markers that 
are used to define prognosis in several oncologic con-
ditions. The AIP immunostaining was weakly positive 
in tumor tissue, in accordance with previous reports in 
non-truncating mutations. However AIP immunos-
taining does not appear to have any prognostic value in 
prolactinomas (18,26). 
The Ki-67 protein is present in the nucleus of a 
dividing cell (G1, S, G2/M phase) but is absent from 
the resting cells (G0 phase). Thus, it can provide 
some information concerning proliferative potential 
of cancer cells and about the prediction of response 
to a certain therapy. Ki-67 labelling in more than 3% 
of the cells is commonly associated with tumor inva-
siveness (27). In GH and PRL secreting adenomas, 
Ki-67 is generally low in the presence of pre-operative 
pharmacological treatment (27). In our study we ob-
served positive immunostaining for Ki-67 in about 
25% of tumoral cells, in samples from the first and 
confirmed in tumor tissue from third surgery. Thus, 
Ki-67 labelling was conserved after dopamine agonist 
treatment, and can be considered an additional mark-
er of aggressiveness and pharmacological resistance in 
our patient.
The tumor suppressor gene p53 controls entry of 
the cells into the cell cycle, on phase G1, and mutations 
on this gene could permit progression of tumor cells. 
The presence of p53 mutations in pituitary tumors is 
rarely described (28), but some authors found a rela-
tionship with proliferative states (29,30). In our patient 
we detected positivity in 10% of the tumoral cells. This 
finding suggests that p53 would not have an important 
role in our patient tumor evolution.
The proto-oncogene c-erbB2 encodes a trans-
membrane receptor protein with tyrosine kinase activ-
ity belonging to the epidermal growth factor receptor 
(EGFR) family. C-erb B2 expression is a marker of tu-
mor aggressiveness in breast cancer (31), but few stu-
dies have assessed c-erbB2 in the pituitary. Our group 
previously reported variable c-erbB2 immunoreactivity 
in somatotropic and lactotrophic tumors and it might 
have some influence on their evolution, considering 
the intimate relationship between c-erb B2 and the 
epidermal growth factor (EGF) (28,30). We recently 
described a strong c-erb staining in aggressive somato-
tropic adenoma in the context of Familial Isolated Pi-
tuitary Adenomas (FIPA) with a 174 frameshift AIP 
mutation (13). In this case, c-erb B2 was negative and 
had no relation to tumor aggressiveness.
In conclusions, the spectrum of AIP mutation-as-
sociated pituitary tumors includes all clinical subtypes. 
AIP mutations confer an aggressive pituitary tumor 
phenotype with at an early age onset, and may be 
screened in childhood-adolescence. AIP mutations are 
likely to represent co-factors in the pathogenesis rather 
than the causative abnormality, confer an aggressive pi-
tuitary tumor phenotype with early age onset, and may 
be screened in childhood-adolescence. 
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